A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study

Study limitation reported by the research below: “Overall survival upper confidence interval (30.0 months) suggests the OS data may not be fully mature at the time of reporting.”